IP Library Granted Patent US 11,897,918
Granted Patent B2
US 11,897,918 · App. 16/297,895 · Granted Feb 13, 2024

Compositions and methods to increase production

Inventors: Samuel Ho (Cambridge, MA); David Parker (Cambridge, MA); Peter Fekkes (Cambridge, MA); Ivna De Souza (Cambridge, MA); Peter Mason (Cambridge, MA); Pirada Allen (Cambridge, MA)
Assignee: Seqirus UK Limited
C07K14/005A61K39/12A61K39/145C12N7/00C12N7/02A61K39/00A61K2039/575C12N2760/16111C12N2760/16134C12N2760/16143C12N2760/16151C12N2760/16234C12N2760/16243C12N2760/16251
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,897,918
App. No.
16/297,895
Granted
Feb 13, 2024
Kind
B2
Abstract

Disclosed herein are methods for increasing protein yield and cellular productivity. Chemical agents facilitate host cell production of biological molecules to increase product yield.

Claims (22)

1. A method for producing influenza virus particles and influenza virus proteins from suspension MDCK cells comprising:

growing or culturing the suspension MDCK cells for a duration of time, at least a portion of which is carried out in the presence of at least one chemical agent selected from the group consisting of fluvastatin, atorvastatin, cerivastatin, lovastatin, mevastatin, pravastatin or isomers thereof;

harvesting the influenza virus particles and influenza virus proteins from the suspension MDCK cells; and

formulating the influenza virus particles and influenza virus proteins into a pharmaceutical composition;

wherein the at least one chemical agent has a concentration of 0.001 μM to 5 μM in culture.

2. The method according to claim 1 , wherein the suspension MDCK cells are infected with an influenza virus.

3. The method according to claim 2 , wherein the at least one chemical agent is added concurrently with influenza virus inoculation of the suspension MDCK cells.

4. The method according to claim 1 , wherein the influenza virus particles and influenza virus proteins produced by the suspension MDCK cells are selected from influenza virus particles, split influenza virions, or influenza virus glycoproteins.

5. The method according to claim 4 , wherein the influenza virus glycoproteins are hemagglutinins.

6. The method according to claim 1 , wherein the yield of the influenza virus particles and influenza virus proteins produced is increased at least 1.5-fold compared to a control, as measured by ELISA.

7. The method according to claim 1 , wherein the at least one chemical agent is fluvastatin or isomers thereof.

8. A method for producing influenza virus particles or influenza virus proteins from suspension MDCK cells comprising:

growing or culturing the suspension MDCK cells for a duration of time, at least a portion of which is carried out in the presence of at least one chemical agent selected from the group consisting of fluvastatin, atorvastatin, cerivastatin, lovastatin, mevastatin, pravastatin or isomers thereof;

harvesting the influenza virus particles or influenza virus proteins from the suspension MDCK cells; and

formulating the influenza virus particles or influenza virus proteins into a pharmaceutical composition;

wherein the at least one chemical agent has a concentration of 0.001 μM to 5 μM in culture.

9. The method according to claim 8 , wherein the suspension MDCK cells are infected with an influenza virus.

10. The method according to claim 9 , wherein the at least one chemical agent is added concurrently with influenza virus inoculation of the suspension MDCK cells.

11. The method according to claim 8 , wherein the influenza virus particles or influenza virus proteins produced by the suspension MDCK cells are selected from influenza virus particles, split influenza virions, or influenza virus glycoproteins.

12. The method according to claim 11 , wherein the influenza virus glycoproteins are hemagglutinins.

13. The method according to claim 8 , wherein the yield of the influenza virus particles or influenza virus proteins produced is increased at least 1.5-fold compared to a control, as measured by ELISA.

14. The method according to claim 8 , wherein the at least one chemical agent is fluvastatin or isomers thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2021
From: NOVARTIS AG
To: SEQIRUS UK LIMITED
Reel/Frame 056898/0884 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2021
From: PARKER, DAVID T.
To: CIBA-GEIGY CORPORATION
Reel/Frame 056899/0092 →
MERGER Recorded Jul 19, 2021
From: SANDOZ AG, CIBA-GEIGY AG
To: NOVARTIS
Reel/Frame 057319/0034 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2019
From: HO, SAMUEL; FEKKES, PETER; DE SOUZA, IVNA; MASON, PETER; SUPHAPHIPHAT, PIRADA
To: NOVARTIS AG
Reel/Frame 050816/0280 →
Priority Claims (1)
EP 14165334 · Apr 18, 2014 · regional
Continuity (2)
Continuation 15304650
Related Publication 20200040040A1 · Feb 6, 2020